FDA deals setback to Sunovion for inhaled COPD therapy

The FDA issued a complete response letter to Sunovion Pharmaceuticals in regards to the new drug application for its eFlow chronic obstructive pulmonary disease drug-device combo.

The investigational eFlow closed-system nebulizer delivers a long-acting muscarinic antagonist bronchodilator, glycopyrrolate, to reduce airflow obstruction in COPD patients.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA deals setback to Sunovion for inhaled COPD therapy appeared first on MassDevice.

from MassDevice http://ift.tt/2r7qfcC